Róbert Královics

CeMM Research Center for Molecular Medicine — Austria

Medicine · Health Sciences

61h-index19.2kcitations253works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(186), Acute Myeloid Leukemia Research(81), Chronic Myeloid Leukemia Treatments(80), Eosinophilic Disorders and Syndromes(75), Kruppel-like factors research(57)

Publications253 total

Purine nucleobases enhance CD8 <sup>+</sup> T cell effector function
2025Open Access
Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)
HemaSphere·2025· 7 citedOpen Access
Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality
Journal of the American College of Cardiology·2024· 14 cited
Evaluation of the &lt;i&gt;ATM&lt;/i&gt; L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms
Haematologica·2024· 1 citedOpen Access
Effects of <i>Tulp4</i> deficiency on murine embryonic development and adult phenotype
Microscopy Research and Technique·2023· 1 citedOpen Access
Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms
Blood·2023· 21 cited
Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)
Blood·2023Open Access
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Leukemia·2023· 65 citedOpen Access
P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA
HemaSphere·2023Open Access
Phenotypic characterization of disease‐initiating stem cells in <i>JAK2</i>‐ or <i>CALR</i>‐mutated myeloproliferative neoplasms
American Journal of Hematology·2023· 12 citedOpen Access
Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
Blood·2022· 4 cited
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
Blood·2022· 43 citedOpen Access
Genetic basis and molecular profiling in myeloproliferative neoplasms
Blood·2022· 128 citedOpen Access
Co‐expression of mutated Jak2 and Calr enhances myeloproliferative phenotype in mice without loss of stem cell fitness
American Journal of Hematology·2022· 1 citedOpen Access
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Leukemia·2022· 102 citedOpen Access
<scp>PD‐L1</scp> overexpression correlates with <scp><i>JAK2</i>‐V617F</scp> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
American Journal of Hematology·2022· 22 citedOpen Access
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
Nature Communications·2022· 10 citedOpen Access
Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials
Blood·2021· 2 cited
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
Nature Communications·2021· 40 citedOpen Access
High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells
Blood Cancer Journal·2021· 3 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Heinz Gisslinger(18), Mario Cazzola(14), Radek C. Skoda(10), Ashot S. Harutyunyan(10), Bettina Gisslinger(10), Thorsten Klampfl(9), Daniela Pietra(9), Elisa Rumi(8), Tiina Berg(8), Jelena D. Milosevic Feenstra(7), Giulio Superti‐Furga(7), Harini Nivarthi(6), Francesco Passamonti(5), Doris Chen(5), William Vainchenker(5), Roland Jäger(5), Stefan N. Constantinescu(5), Josef T. Prchal(5), Alessandro M. Vannucchi(5), Andreas Buser(4)